Intravenous peramivir for treatment of influenza in hospitalized patients

Ison, Michael G., Fraiz, Joseph, Heller, Barry, Jauregui, Luis, Mills, Graham, O'Riordan, William, O'Neil, Brian, Playford, E. Geoffrey, Rolf, J. Douglass, Sada-Diaz, Eduardo, Elder, Jenna, Collis, Phil, Hernandez, Jaime E. and Sheridan, William P. (2014) Intravenous peramivir for treatment of influenza in hospitalized patients. Antiviral Therapy, 19 4: 349-361. doi:10.3851/IMP2680

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Ison, Michael G.
Fraiz, Joseph
Heller, Barry
Jauregui, Luis
Mills, Graham
O'Riordan, William
O'Neil, Brian
Playford, E. Geoffrey
Rolf, J. Douglass
Sada-Diaz, Eduardo
Elder, Jenna
Collis, Phil
Hernandez, Jaime E.
Sheridan, William P.
Title Intravenous peramivir for treatment of influenza in hospitalized patients
Journal name Antiviral Therapy   Check publisher's open access policy
ISSN 1359-6535
Publication date 2014-08-28
Year available 2014
Sub-type Article (original research)
DOI 10.3851/IMP2680
Volume 19
Issue 4
Start page 349
End page 361
Total pages 13
Place of publication London, United Kingdom
Publisher International Medical Press
Collection year 2015
Language eng
Formatted abstract
Background: Influenza causes over 200,000 hospitalizations a year in the United States, but few antiviral treatment studies have focused on patients hospitalized with influenza. This open-label, randomized study was initiated during the 2009 H1N1 pandemic to help assess the antiviral activity, safety and tolerability of 5–10 days treatment with two different dosing regimens of the intravenous neuraminidase inhibitor, peramivir, in hospitalized subjects with influenza.

Methods: Quantitative virology was done on nasopharyngeal swab specimens from subjects ≥6 years of age to measure change from baseline in tissue culture infective dose (primary end point) and quantitative viral RNA levels by real-time PCR. Clinical end points included time to clinical resolution, a composite end point of four vital signs and oxygen saturation.

Results: A total of 234 hospitalized patients were randomized to peramivir 300 mg twice daily or 600 mg once daily; 127 had laboratory confirmed influenza. In those with detectable virus at baseline, viral titres declined without differences between regimens. There were no significant differences in clinical or virological end points between treatment arms, and apparent differences were explained by baseline disease severity differences in the groups. Peramivir was generally safe and well tolerated for treated patients hospitalized with pandemic influenza with outcomes similar to those described in the literature.

Conclusions: This open-label trial of intravenous peramivir in subjects hospitalized predominantly with 2009 influenza A (H1N1) demonstrated that once- or twice-daily administration was associated with decreases in viral shedding and clinical improvement.
Keyword 2009 H1N1 influenza
Emergency use authorization
Renal replacement therapy
United States
Virus infection
A H1N1
Neuraminidase inhibitors
High risk
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2015 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 7 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 01 Mar 2015, 01:00:15 EST by System User on behalf of School of Medicine